INTERVIEW: SillaJen CEO Confident On ‘Dream’ Cancer Therapy (Pt. 2)
This article was originally published in PharmAsia News
Executive Summary
After years of convincing the medical industry about the value of its novel cancer immunotherapy, South Korea’s SillaJen may be stepping closer to its goal of commercializing the “dream cancer therapy.” The bioventure’s CEO, Moon Eun-sang, shares his views on the product and SillaJen’s future in this second and final part of an exclusive interview with PharmAsia News.
You may also be interested in...
Amgen T-VEC’s Remaining Challenges: Getting To Market, Staying Relevant
After overwhelming but unenthusiastic endorsement from FDA’s advisory committee, the metastatic melanoma immunotherapy could still be hobbled by problematic trials as Amgen seeks approval path and prescriptions in rapidly changing disease space.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Korea Govt Partners With J&J To Bring In Local JLABS Site
In collaboration with the national health ministry, J&J’s JLAB program is coming to South Korea as its third destination in Asia, underscoring the country’s increasing need to access multinationals’ know-how and its growing impact on the global biotech landscape and innovation.